June 29th 2020
Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.
April 25th 2020
Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.
April 24th 2020
Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.
March 18th 2020
Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses data with AMG 420 in multiple myeloma.
March 5th 2020
Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.
April 18th 2019
Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses data for the standard triplet regimens in the treatment of patients with relapsed/refractory myeloma.
April 8th 2019
Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses treatment approaches for patients with relapsed/refractory multiple myeloma.
March 15th 2019
Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses preliminary data on bb21217 in multiple myeloma.
October 1st 2018
Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.
September 12th 2018
Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the impact of bb2121 in myeloma.
June 25th 2018
Noopur Raje, MD, director Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the tolerability of bb2121 as a treatment for patients with multiple myeloma.
December 8th 2014
Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.